Glucose Fresenius Kabi (Glucose Monohydrate)

Glucose Fresenius Kabi is indicated for several clinical situations where rapid provision of carbohydrate calories or plasma volume support is needed.

• Treatment of hypoglycemia when oral glucose is not feasible.
• Component of parenteral nutrition regimens to supply energy.
• Fluid replacement in patients requiring intravenous volume expansion.
• Support during perioperative periods to maintain blood glucose levels.
• Management of electrolyte-free water deficits in certain clinical settings.
• Dilution of other intravenous medications when a compatible carbohydrate source is required.
• Provision of caloric support in patients with impaired oral intake or gastrointestinal dysfunction.

When administered intravenously, Glucose Fresenius Kabi may be associated with a range of adverse reactions, most of which are related to the rapid infusion of a carbohydrate solution.

Common

• Transient hyperglycemia, especially in patients with impaired insulin response.
• Local irritation or pain at the infusion site.
• Nausea or mild gastrointestinal discomfort.
• Electrolyte shifts, such as mild hyponatremia.
• Mild headache related to rapid osmotic changes.
• Temporary increase in serum osmolality.

Serious

• Severe hyperglycemia leading to osmotic diuresis.
• Fluid overload and pulmonary edema in patients with compromised cardiac function.
• Hypersensitivity reactions, including rash, urticaria, or anaphylaxis.
• Metabolic acidosis in the setting of massive glucose infusion.

Prior to using Glucose Fresenius Kabi, clinicians should evaluate patient-specific factors to minimize risks associated with intravenous glucose administration.

• Assess baseline blood glucose and adjust infusion rate in diabetic or insulin‑dependent patients.
• Monitor fluid balance and cardiac status to avoid overload, especially in heart failure or renal impairment.
• Use caution in patients with known hypersensitivity to glucose solutions or excipients.
• Evaluate electrolyte levels, particularly sodium and potassium, before and during therapy.
• Avoid rapid bolus administration unless clinically indicated.
• Consider compatibility with other IV drugs to prevent precipitation.

Glucose Fresenius Kabi can interact with other intravenous agents or affect the pharmacodynamics of certain medications; awareness of these interactions helps ensure safe co‑administration.

Avoid

• Concurrent infusion with high‑dose insulin without appropriate monitoring.
• Mixing with calcium‑containing solutions that may precipitate.
• Simultaneous administration with hypertonic saline solutions, which can exacerbate hyperosmolar states.

Use with caution

• Co‑administration with diuretics may increase risk of electrolyte disturbances.
• Use alongside beta‑blockers, as they may mask hypoglycemia symptoms.
• Concurrent use with other carbohydrate‑containing fluids requires careful calculation of total caloric load.
• Administration together with vasopressors may necessitate close hemodynamic monitoring due to potential fluid shifts.